Motley Fool Wealth Management LLC Reduces Position in Regeneron Pharmaceuticals, Inc. $REGN

Motley Fool Wealth Management LLC lessened its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 19.0% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 7,792 shares of the biopharmaceutical company’s stock after selling 1,830 shares during the period. Motley Fool Wealth Management LLC’s holdings in Regeneron Pharmaceuticals were worth $6,015,000 at the end of the most recent reporting period.

Several other large investors also recently bought and sold shares of the business. TD Private Client Wealth LLC grew its stake in Regeneron Pharmaceuticals by 9.7% during the 4th quarter. TD Private Client Wealth LLC now owns 169 shares of the biopharmaceutical company’s stock valued at $130,000 after acquiring an additional 15 shares in the last quarter. MCF Advisors LLC grew its stake in Regeneron Pharmaceuticals by 50.0% during the 4th quarter. MCF Advisors LLC now owns 45 shares of the biopharmaceutical company’s stock valued at $35,000 after acquiring an additional 15 shares in the last quarter. CYBER HORNET ETFs LLC grew its stake in Regeneron Pharmaceuticals by 6.0% during the 4th quarter. CYBER HORNET ETFs LLC now owns 301 shares of the biopharmaceutical company’s stock valued at $232,000 after acquiring an additional 17 shares in the last quarter. Meyer Handelman Co. grew its stake in Regeneron Pharmaceuticals by 0.6% during the 4th quarter. Meyer Handelman Co. now owns 2,878 shares of the biopharmaceutical company’s stock valued at $2,221,000 after acquiring an additional 18 shares in the last quarter. Finally, Gateway Investment Advisers LLC grew its stake in shares of Regeneron Pharmaceuticals by 4.3% in the 4th quarter. Gateway Investment Advisers LLC now owns 464 shares of the biopharmaceutical company’s stock valued at $358,000 after buying an additional 19 shares during the period. Hedge funds and other institutional investors own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Stock Performance

NASDAQ:REGN opened at $616.18 on Wednesday. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.96 and a current ratio of 3.57. Regeneron Pharmaceuticals, Inc. has a fifty-two week low of $503.25 and a fifty-two week high of $821.11. The stock has a market capitalization of $65.14 billion, a P/E ratio of 15.01, a PEG ratio of 1.34 and a beta of 0.25. The company has a 50 day moving average price of $701.59 and a 200 day moving average price of $741.02.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings results on Wednesday, April 29th. The biopharmaceutical company reported $9.47 EPS for the quarter, topping the consensus estimate of $8.91 by $0.56. Regeneron Pharmaceuticals had a net margin of 29.65% and a return on equity of 13.16%. The firm had revenue of $3.61 billion for the quarter, compared to analyst estimates of $3.48 billion. During the same period last year, the business earned $8.22 EPS. Regeneron Pharmaceuticals’s revenue for the quarter was up 19.0% compared to the same quarter last year. Equities research analysts forecast that Regeneron Pharmaceuticals, Inc. will post 37.44 EPS for the current year.

Regeneron Pharmaceuticals Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Thursday, June 4th. Investors of record on Wednesday, May 20th were paid a dividend of $0.94 per share. This represents a $3.76 annualized dividend and a yield of 0.6%. The ex-dividend date was Wednesday, May 20th. Regeneron Pharmaceuticals’s dividend payout ratio (DPR) is currently 9.16%.

Analysts Set New Price Targets

REGN has been the subject of several analyst reports. Morgan Stanley increased their price target on shares of Regeneron Pharmaceuticals from $769.00 to $796.00 and gave the company an “equal weight” rating in a research note on Friday, April 10th. Barclays dropped their price target on shares of Regeneron Pharmaceuticals from $923.00 to $917.00 and set an “overweight” rating for the company in a research note on Thursday, April 30th. Canaccord Genuity Group dropped their price target on shares of Regeneron Pharmaceuticals from $1,057.00 to $875.00 and set a “buy” rating for the company in a research note on Tuesday, May 19th. Wells Fargo & Company dropped their price target on shares of Regeneron Pharmaceuticals from $800.00 to $700.00 and set an “equal weight” rating for the company in a research note on Monday, May 18th. Finally, JPMorgan Chase & Co. dropped their price target on shares of Regeneron Pharmaceuticals from $950.00 to $850.00 and set an “overweight” rating for the company in a research note on Monday, May 18th. Two equities research analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating and ten have assigned a Hold rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $792.65.

Insider Buying and Selling

In other Regeneron Pharmaceuticals news, Director Arthur F. Ryan sold 100 shares of Regeneron Pharmaceuticals stock in a transaction on Friday, May 1st. The shares were sold at an average price of $705.24, for a total value of $70,524.00. Following the transaction, the director directly owned 17,503 shares in the company, valued at approximately $12,343,815.72. The trade was a 0.57% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 6.97% of the stock is owned by corporate insiders.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.